Background

Jack joined the Burnet Institute in 2019 to work on multiple projects in the Eliminate Hepatitis C Partnership.

He completed his honours with the Burnet in 2017. His thesis explored pathways to increase access to hepatitis C treatment in pharmacies that provide opioid substitution therapy.

Jack has interests in both qualitative and quantitative research, AOD harm reduction, mental health, and blood-borne viruses.

Qualifications

• 2017: BHSc (Public Health Hons), La Trobe University, Melbourne, Australia
• 2016: BHSc, La Trobe University, 2016, Melbourne, Australia

Projects (1)

Current (1)

• 

  Feasibility study for a potential medically supervised injecting centre/drug consumption service for the ACT

Publications (2)

2020 (1)

• Directly observed hepatitis C treatment with opioid substitution therapy in community pharmacies: A qualitative study.
  Gunn J, Higgs P
  Res Social Adm Pharm. 2020 Jan; 16(9):1298-1301

2019 (1)

• Pharmacy-led hepatitis C treatment pathways to help ensure elimination.
  Gunn J, Higgs P
  Lancet Gastroenterol Hepatol. 2019 Jan; 4(1):12-13